Anthropic Ships Sonnet 5 With Agentic Safety and Pricing Details
1 July 20265 min read
Illustrative image. Cedar S. Insights uses editorial stock photography; images do not depict specific events described in articles.
FDA approved daratumumab and hyaluronidase-fihj with bortezomib, lenalidomide and dexamethasone for adults with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
The approval brings a daratumumab-containing regimen into a frontline population where treatment choice shapes years of disease management.
For hematology practices, frontline approvals affect pathway design, patient selection and long-term sequencing.
Why It Matters
Frontline myeloma regimens are becoming more intensive and antibody-based even for transplant-ineligible patients.
What to Watch
Watch real-world tolerance, access and sequencing after frontline daratumumab exposure.
Primary Sources
Our sourcing: Cedar S. Insights provides source-led editorial analysis. Reported company, institutional and regulatory claims are attributed to their original sources unless stated otherwise.
Corrections: If a material factual error is identified, Cedar S. Insights will update the relevant article and preserve the distinction between the corrected statement and supporting evidence.
Topics
FDAMultiple MyelomaDaratumumabHematology